Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Flufenamic acid in rheumatoid arthritis.

× No keyword cloud information.

6 in total

1. Evaluation of drug therapy in rheumatoid arthritis-study of flufenamic acid.

Authors: E L COODLEY
Journal: West Med Med J West Date: 1963-07

2. DIAGNOSTIC criteria for rheumatoid arthritis: 1958 revision by a committee of the American Rheumatism Association.

Authors:
Journal: Ann Rheum Dis Date: 1959-03 Impact factor: 19.103

3. New drugs. VII. A controlled trial of flufenamic acid therapy in rheumatoid arthritis.

Authors: M E Fearnley; H C Masheter
Journal: Ann Phys Med Date: 1966-05

4. New drugs. 8. Flufenamic acid in rheumatoid arthritis. Comparison with aspirin and the results of extended treatment.

Authors: M R Simpson; N R Simpson; H C Masheter
Journal: Ann Phys Med Date: 1966-05

5. Mefenamic acid and flufenamic acid compared with aspirin and phenylbutazone in rheumatoid arthritis.

Authors: D E Barnardo; H L Currey; R M Mason; W R Fox; M Weatherall
Journal: Br Med J Date: 1966-08-06

6. Anti-inflammatory and antipyretic properties of N-(alpha,alpha,alpha-trifluoro-m-tolyl) anthranilic acid (CI-440; flufenamic acid).

Authors: C V WINDER; J WAX; B SERRANO; E M JONES; M L McPHEE
Journal: Arthritis Rheum Date: 1963-02

6 in total

8 in total

1. Rational design of agonists for bitter taste receptor TAS2R14: from modeling to bench and back.

Authors: Antonella Di Pizio; Lukas A W Waterloo; Regine Brox; Stefan Löber; Dorothee Weikert; Maik Behrens; Peter Gmeiner; Masha Y Niv
Journal: Cell Mol Life Sci Date: 2019-06-24 Impact factor: 9.261

Review 2. Current therapy of rheumatoid arthritis.

Authors: E J Kamin; C V Multz
Journal: Calif Med Date: 1969-01

3. Assessment of drugs in out-patients with rheumatoid arthritis. Evaluation of methods and a comparison of mefenamic and flufenamic acids with phenylbutazone and aspirin.

Authors: R M Mason; D E Barnardo; W R Fox; M Weatherall
Journal: Ann Rheum Dis Date: 1967-09 Impact factor: 19.103

4. In vitro analysis of flufenamic acid activity against Candida albicans biofilms.

Authors: Alba A Chavez-Dozal; Maximillian Jahng; Hallie S Rane; Kingsley Asare; Vibhati V Kulkarny; Stella M Bernardo; Samuel A Lee
Journal: Int J Antimicrob Agents Date: 2013-10-01 Impact factor: 5.283

5. Antirheumatic drugs: clinical pharmacological and therapeutic aspects.

Authors: C J Smyth; J F Bravo
Journal: Drugs Date: 1975 Impact factor: 9.546

6. Prostaglandins, nonsteroidal anti-inflammatory agents and eye disease.

Authors: S M Podos
Journal: Trans Am Ophthalmol Soc Date: 1976

7. Low concentration flufenamic acid enhances osteogenic differentiation of mesenchymal stem cells and suppresses bone loss by inhibition of the NF-κB signaling pathway.

Authors: Xuenan Liu; Zheng Li; Hao Liu; Yuan Zhu; Dandan Xia; Siyi Wang; Ranli Gu; Weiliang Wu; Ping Zhang; Yunsong Liu; Yongsheng Zhou
Journal: Stem Cell Res Ther Date: 2019-07-19 Impact factor: 6.832

8. Flufenamic Acid Inhibits Adipogenic Differentiation of Mesenchymal Stem Cells by Antagonizing the PI3K/AKT Signaling Pathway.

Authors: Xuenan Liu; Zheng Li; Hao Liu; Yuan Zhu; Dandan Xia; Siyi Wang; Ranli Gu; Ping Zhang; Yunsong Liu; Yongsheng Zhou
Journal: Stem Cells Int Date: 2020-03-16 Impact factor: 5.443

8 in total